Vir Biotechnology Announces Topline Data from Phase 2 ...

Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness.

Vir Biotechnology Announces Topline Data from Phase 2

PENINSULA (NCT05567783) is the first Phase 2 outpatient trial to evaluate the role of a monoclonal antibody in the prevention of influenza A ...

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials.

Vir Biotechnology Announces Topline Data from Phase 2 ...

Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness. Explore Alta ...

Vir Biotechnology, Inc. - Press Release Distribution and Management

Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial ... (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of ...

Lilly, Vir Biotechnology and GSK announce positive topline data ...

Eli Lilly and Company, Vir Biotechnology, Inc. and GlaxoSmithKline plc today announced topline data from the expanded Phase 2 BLAZE-4 trial ...

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that ...

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data ...

(NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk ...

Vir's GSK-Backed Flu Vaccine Candidate Fails Phase II Trial

Topline data from the Phase II PENINSULA study showed that Vir Biotechnology ... biotech announced Thursday. Patients inoculated with the ...

Vir Biotechnology Announces Clinical Advances Across Hepatitis ...

Phase 2 SOLSTICE Safety and Efficacy Data in Hepatitis Delta Trial at Week 24 to Be Presented – – Oral and Five Poster Presentations ...

Vir Biotechnology Announces Topline Data from Phase 2 ... - Gale

Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness.

The Antibody Society on LinkedIn: Press Release: Vir Biotechnology ...

Press Release: Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness | ...

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce ...

(Nasdaq: VBIV) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating BRII-835 (VIR-2218), an ...

Barry Clinch on LinkedIn: Press Release: Vir Biotechnology ...

Barry Clinch's Post · Press Release: Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention ...

Press Release - Brii Biosciences

Brii Biosciences Announces Topline Interim Results of Phase 2 Study ... Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 ...

News Details - Vir Biotechnology, Inc. - Investor Relations

(Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart ...

Sotrovimab: First Approval - PMC

GlaxoSmithKline. Lilly, Vir Biotechnology and GSK announce positive topline data from the phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR ...

https://investors.vir.bio/Sitemap.ashx

... Phase-2-SOLSTICE-Hepatitis-Delta-Trial-Data-Update-at-EASL-2024-Investor ... Announces-Clinical-Advances-Across-Hepatitis-Delta-and-Hepatitis-B ...

Vir Biotechnology, Inc.

The full analysis of data from the Phase 2 ... For example, in July 2023, we announced that our Phase 2 clinical trial of VIR-2482 for the ...

Vir Biotechnology's PENINSULA trial fails to meet efficacy endpoints

Vir Biotechnology's Phase II PrevEntioN of IllNesS DUe to InfLuenza ... two data readouts across our hepatitis B and hepatitis D programmes in ...